feedback

Course Directors

Farnaz Dadmanesh, MD
Farnaz Dadmanesh, MD

Director, Breast Pathology
Co-Director, Pathology Outreach
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Laura H. Tang, MD, PhD
Laura H. Tang, MD, PhD

Attending Pathologist
Memorial Sloan Kettering Cancer Center
New York, New York

Faculty

Joseph Chao
Joseph Chao, MD

Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research
Gastrointestinal Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California

Heather L. McArthur
Heather L. McArthur, MD, MPH

Medical Director, Breast Oncology
Hematology/Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Accredited by

Medical Learning Institute, Inc.

View Activity Materials

Activity Description

In the evolving era of precision cancer care, increasing emphasis is placed on detecting molecular alterations driving the development of specific cancers and targeting them with matched therapies or combinations that can yield the best outcomes for patients. Such is the case with HER2—and, more recently, also HER3 and TROP2—which are gaining growing interest as relevant targets in different malignancies. This is particularly important now, as a number of new targeted therapies have started to reach the clinic and are expected to change practice, and many others are showing great promise in clinical trials in breast, gastrointestinal, lung, and other tumors. Pathology professionals play an essential role in realizing the potential of precision cancer care by carrying out optimal predictive testing.

This PeerView on-demand activity, based on a recent symposium at the United States and Canadian Academy of Pathology (USCAP) 108th Annual Meeting, features a panel of leading pathology and oncology experts, who share their insights into recent advances in testing and treatment of various HER2-altered cancers, including breast, gastrointestinal, lung, and other tumors. The emerging roles of HER3 and TROP2 as potential new targets are reviewed as well. In addition, they provide useful guidance to improve testing and best practices for interpretation, as well as interdisciplinary collaboration, all for the benefit of the patients.

Target Audience

This activity has been designed to meet the educational needs of pathologists, laboratory professionals, and other healthcare professionals involved in the testing and treatment of patients with HER2-expressing or HER2-mutant cancers.

Educational Objectives

Upon completion of this activity, participants should be better able to:
  • Review evidence-based guidelines and expert recommendations regarding HER2 testing and interpretation of results in breast, gastric, colorectal, non–small cell lung, and other cancers
  • Evaluate the characteristics, mechanisms of action, and efficacy/safety evidence of established and emerging HER2-targeted agents for the management of patients with advanced HER2-expressing or HER2-mutant cancers
  • Implement appropriate methods and best practices for HER2 testing and interpretation to guide integration of the latest HER2-targeted therapies into individualized treatment plans for patients with advanced HER2-expressing or HER2-mutant cancers either in the context of clinical practice or through clinical trial participation

Providership, Credit, and Support


This CME/CC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

This activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., Puma Biotechnology, Inc., and Seattle Genetics.

Physician Continuing Medical Education

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Certification Statement

The activity titled “Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists” has been registered to offer 1.5 Lifelong Learning (Part II) credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Participation information will be shared with ABPath through the ACCME’s Program and Activity Reporting System (PARS). Blinded individual or aggregated participant data may be shared with the funder of the activity.

Faculty Disclosures

Co-Chairs
Farnaz Dadmanesh, MD
Director, Breast Pathology
Co-Director, Pathology Outreach
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Farnaz Dadmanesh, MD, has no financial interests/relationships or affiliations in relation to this activity.

Laura H. Tang, MD, PhD
Attending Pathologist
Memorial Sloan Kettering Cancer Center
New York, New York

Laura H. Tang, MD, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Faculty
Joseph Chao, MD
Assistant Clinical Professor
Department of Medical Oncology & Therapeutics Research
Gastrointestinal Cancer Program
City of Hope Comprehensive Cancer Center
Duarte, California

Joseph Chao, MD, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Amgen Inc.; Eli Lilly and Company; Foundation Medicine; MacroGenics, Inc.; and Merck & Co., Inc.
Grant/Research Support from Merck & Co., Inc.
Speakers Bureau participant with Merck & Co., Inc.

Heather L. McArthur, MD, MPH
Medical Director, Breast Oncology
Hematology/Oncology
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California

Heather L. McArthur, MD, MPH, has a financial interest/relationship or affiliation in the form of:
Consultant and/or Advisor for AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc; Immunomedics; Merck & Co., Inc.; Pfizer Inc.; Puma Biotechnology, Inc.; and Seattle Genetics.
Grant/Research Support from AstraZeneca; Bristol-Myers Squibb; BTG International Ltd.; MedImmune; and Merck & Co., Inc. Research support to Institution.

Planning Committee Disclosures

The planners from Medical Learning Institute, Inc., the accredited provider, and PeerView Institute for Medical Education, the joint provider, do not have any financial relationships with an ACCME-defined commercial interest related to the content of this accredited activity during the past 12 months unless listed below.

Content/Peer Reviewer Disclosures

The following Content/Peer Reviewers have nothing to disclose:

Pamela Ash, RN, MSN, CBCN
Jim Zhai, MD, FCAP

Disclosure of Unlabeled Use

This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation

There are no fees for participating in or receiving credit for this accredited activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and will be emailed to you upon completion. You will receive your certificate from email@email.peerviewpress.com. If you have questions regarding the receipt of your emailed certificate, please contact via email at info@PeerView.com.

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CC credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CC credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

About This CME/CC Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

Copyright © 2000-2020, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.